Interaction between lead acetate and morphine on antinociception in mice by formalin test

General Pharmacology

Volumn 30, Issue 4, 1998, Pages 489-493

  Nikfar, Shekoufeh ^a   Abdollahi, Mohammad ^a   Sharifzadeh, Mohammad ^a   Eftekhar, Nazanin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antinociception; Formalin test; Lead; Morphine

Indexed keywords

FORMALDEHYDE; LEAD ACETATE; MORPHINE; OPIATE RECEPTOR;

ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS, OPIOID; ANIMALS; MALE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; ORGANOMETALLIC COMPOUNDS; PAIN MEASUREMENT;

EID: 0032053421     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00283-8     Document Type: Article

References (33)

1. Abbot F. V., Melzack R., Samuel C. Morphine analgesia in the tail flick and formalin pain test in mediated by different neural systems. Exp. Neurol. 75:1982;644-651.
2. Abram S. E., Olson E. E. Systemic opioids do not suppress spinal sensitization after subcutaneous formalin in rats. Anesthesiology. 80:1994;1114-1119.
3. Bailey C., Kitchen I. Ontogenesis of proenkephalin products in rat striatum and the inhibitory effects of low level lead exposure. Dev. Brain Res. 22:1985;75-79.
4. Baraldi M., Zanoli P., Rossi T., Borella P., Caselgrandi E., Petraglia F. Neurobehavioural and neurochemical abnormalities of pre- and postnatally lead exposed rats. zinc, copper and calcium status Neurobehav. Toxicol. Teratol. 7:1985;499-509.
5. Bondy S. C., Hong J. S., Tilson H. A., Walsh T. J. Effects of triethyl lead on hot plate responsiveness and biochemical properties of hippocampus. Pharmac. Biochem. Behav. 22:1985;1007-1011.
6. 14C-dopamine in rats striatal slices. Naunyn-Schmiedeberg's Arch. Pharmac. 284:1974;159-165.
7. Coderre T. J., Katz J., Vaccarino A. L., Melzack R. Contribution of central neuroplasticity to pathological pain. review of clinical and experimental evidence Pain. 52:1993;259-285.
8. Davis J. M., Elias R. W., Grant L. D. Current issues in human lead exposure and regulation of lead. Neurotoxicology. 14:1993;15-28.
9. Dennis S. G., Melzack R. Pain modulation by 5-hydroxytryptaminergic agents and morphine as measured by 3 pain tests. Exp. Neurol. 69:1980;260-270.
10. Dennis S. G., Melzack R., Gutman S., Boucher F. Pain modulation by adrenergic agents and morphine as measured by 3 pain tests. Life Sci. 26:1980;1247-1259.
11. Gosnell B. A., Majehrzak M. J. Centrally administered peptides stimulate saccharine intake in nondeprived rats. Pharmac. Biochem. Behav. 33:1989;805-810.
12. Govoni S., Memo M., Lucchi L., Spano P. F., Trabucchi M. Brain neurotransmitter system and chronic lead intoxication. Phamac. Res. Commun. 12:1980;447-460.
13. Jackson H. C., Kitchen I. Prenatal lead exposure impairs opioid but not non-opioid stress-induced antinociception in developing rats. Br. J. Pharmac. 97:1989;1338-1342.
14. Jacquet Y. F., Saederup E., Squires R. F. Non-streospecific excitatory actions of morphine may be due to GABA-A receptor blockade. Eur. J. Pharmac. 138:1987;285-288.
15. Kitchen I., McDowell J. Impairment of ketocyclazocine antinociception in rats by prenatal lead exposure. Toxicol. Lett. 26:1985;101-105.
16. Kitchen I., McDowell J., Winder C., Wilson J. M. Low-level lead exposure alters morphine antinociception in neonatal rats. Toxic. Lett. 22:1984;119-123.
17. Kuschinsky K. Evidence that morphine increases dopamine utilization in corpora striata of rats. Experientia. 29:1973;1365-1366.
18. MacDermott A. B., Mayer M. M., Westbrook G. L., Smith S. J., Barker J. L. NMDA-receptor activation increases cytoplasmic calcium concentraion in cultured spinal cord neurons. Nature. 321:1986;519-522.
19. McDowell J., Kitchen I. Prenatal lead exposure alters the development of δ but not μ opioid receptors in rat brain. Br. J. Pharmac. 94:1988;933-937.
20. Meller S. T., Gebhart G. F. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain. 52:1993;127-136.
21. Murray C. W., Porreca F., Cowan A. Methodological refinements to the mouse paw formalin-test. an animal model of tonic pain J. Pharmac. Methods. 20:1988;175-186.
22. Nikfar S., Abdollahi M., Etemad F., Sharifzadeh M. Effects of sweetening agents on morphine-induced analgesia in mice by formalin-test. Gen. Pharmac. 29:1997;583-586.
23. Nowak L. M., Bregestrovski P., Ascher P., Herbert A., Prochiantz A. Magnesium gates glutamate activated channels in mice central neurons. Nature. 307:1984;462-465.
24. Ramabadran K., Bansinath M. A critical analysis of the experimental evaluation of nociceptive reactions in animals. Pharm. Res. 3:1986;263-270.
25. Rang H. P., Dale M. M., Ritter J. M. Pharmacology. 3:1995;Churchill-Livingston, New York. pp. 614-616.
26. Rosland J. H., Tjølsen A., Mæhle B., Hole K. The formalin-test in mice. effect of formalin concentration Pain. 42:1990;235-242.
27. Silbergeld E. K. Interaction of lead Ca on the synaptosomal uptake of dopamine and choline. Life Sci. 20:1977;309-318.
28. Silbergeld E. K., Fales J. T., Goldberg A. M. The effects of inorganic lead on the neuromuscular junction. Neuropharmacology. 13:1974;795-801.
29. Simons T. J. B. Lead-calcium interaction in cellular lead toxicity. Neurotoxicology. 14:1993;77-86.
30. Sliwa-Tomczok W., Tomczok J., Malysiak N. Effect of acute lead intoxication on the ultrastructure of neutrophils in the peripheral blood of the rat. Exp. Pathol. 43:1991;149-154.
31. Struźyńska L., Rafałowska U. The effect of lead on dopamine, GABA and histidine spontaneous and KCl-dependent releases from rat brain synaptosomes. Acta Neurobiol. Exp. 54:1994;201-207.
32. Vickers C., Paterson A. T. Two types of chronic lead treatment in C57BL/6 mice. interaction with behavioural determinants of pain Life Sci. 39:1986;47-53.
33. Yamamoto T., Yaksh T. L. Comparison of the antinociceptive effects of pre and posttreatment with morphine and MK801, an NMDA antagonist, on the formalin test in the rat. Anesthesiology. 77:1992;757-763.